In much the same way that they’re designed to expand wearers’ upper airways, Vivos Therapeutics’ slate of oral appliances have now expanded their FDA indications, too. Collectively known as the ...

Vivos Therapeutics (NASDAQ:VVOS) shares rallied premarket on Wednesday after the medtech firm gained first ever FDA 510(k) clearance for oral device treatment of severe obstructive sleep apnea (OSA).

Credit: Vivos Therapeutics. The FDA clearance was based on data from 73 patients with severe OSA. The Food and Drug Administration (FDA) has cleared the Vivos CARE (complete airway repositioning ...

(Reuters) -Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device for severe obstructive sleep apnea (OSA), leading a massive rally in the company's shares before ...

SIOUX CITY (KTIV) - This past month Jessica Bowman has walked you through the long-term health effects of untreated sleep apnea. Medical experts have shown you, there are options to improve your sleep ...

From leaving your phone in another room to investing in blackout curtains and white noise machines, there’s no shortage of ...

ATLANTA -- An oral appliance for people with obstructive sleep apnea (OSA) was noninferior to continuous positive airway pressure (CPAP) for reducing 24-hour mean arterial blood pressure (BP) in ...

NEW YORK (Reuters Health) - People with mild to moderate sleep apnea may benefit more from breathing pressurized air via a facemask at night than from wearing an oral device while they sleep, Chinese ...

Inspire Medical Systems, a developer of neurostimulation therapies for the treatment of obstructive sleep apnea (OSA), recently received approval from the U.S. Food and Drug Administration (FDA) to ...